Immunodominance hierarchy after seasonal influenza vaccination

References

• Krammer F, Smith GJD, Fouchier RAM, et al. Influenza. Nat Rev Dis Primers. 2018;4:1–21.
   PubMed Web of Science ®Google Scholar
• WHO. Fact Sheets – Seasonal Influenza. [accessed 2020 Jul 5]. Available from: https://www.who.int/es/news-room/fact-sheets/detail/influenza-(seasonal).
   Google Scholar
• Paget J, Spreeuwenberg P, Charu V, et al. Global mortality associated with seasonal influenza epidemics: new burden estimates and predictors from the GLaMOR project. J Glob Health. 2019;9:1–12.
   Web of Science ®Google Scholar
• Preaud E, Durand L, Macabeo B, et al. Annual public health and economic benefits of seasonal influenza vaccination: a European estimate. BMC Public Health. 2014;14:1–12.
   PubMed Web of Science ®Google Scholar
• Molinari NAM, Ortega-Sanchez IR, Messonnier ML, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007;25:5086–5096.
   PubMed Web of Science ®Google Scholar
• Belongia EA, Skowronski DM, McLean HQ, et al. Repeated annual influenza vaccination and vaccine effectiveness: review of evidence. Expert Rev Vaccines. 2017;16:723–736.
   PubMed Web of Science ®Google Scholar
• Yu X, Tsibane T, McGraw PA, et al. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature. 2008;455:532–536.
   PubMed Web of Science ®Google Scholar
• Altman MO, Angeletti D, Yewdell JW. Antibody immunodominance: the key to understanding influenza virus antigenic drift. Viral Immunol. 2018;31:142–149.
   PubMed Web of Science ®Google Scholar
• Yu ED, Grifoni A, Sutherland A, et al. Balanced cellular and humoral immune responses targeting multiple antigens in adults receiving a quadrivalent inactivated influenza vaccine. Vaccines (Basel). 2021;9. doi:10.3390/vaccines9050426.
   Web of Science ®Google Scholar
• Nelson MI, Holmes EC. The evolution of epidemic influenza. Nat Rev Genet. 2007;8:196–205.
   PubMed Web of Science ®Google Scholar
• Krammer F. The human antibody response to influenza A virus infection and vaccination. Nat Rev Immunol. 2019;19:383–397.
   PubMed Web of Science ®Google Scholar
• Aydillo T, Escalera A, Strohmeier S, et al. Pre-existing hemagglutinin stalk antibodies correlate with protection of lower respiratory symptoms in Flu-infected transplant patients. Cell Rep Med. 2020;1. doi:10.1016/J.XCRM.2020.100130.
   PubMedGoogle Scholar
• Jegaskanda S, Andrews SF, Wheatley AK, et al. Hemagglutinin head-specific responses dominate over stem-specific responses following prime boost with mismatched vaccines. JCI Insight. 2019;4. doi:10.1172/jci.insight.129035.
   PubMed Web of Science ®Google Scholar
• Angeletti D, Yewdell JW. Understanding and manipulating viral immunity: antibody immunodominance enters center stage. Trends Immunol. 2018;39:549–561.
   PubMed Web of Science ®Google Scholar
• Caton AJ, Brownlee GG, Yewdell JW, et al. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell. 1982;31:417–427.
   PubMed Web of Science ®Google Scholar
• Gerhard W, Yewdell J, Frankel ME, et al. Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies. Nature. 1981;290:713–717.
   PubMed Web of Science ®Google Scholar
• Sriwilaijaroen N, Suzuki Y. Molecular basis of the structure and function of H1 hemagglutinin of influenza virus. Proc Jpn Acad Ser B Phys Biol Sci. 2012;88:226–249.
   PubMed Web of Science ®Google Scholar
• Liu STH, Behzadi MA, Sun W, et al. Antigenic sites in influenza H1 hemagglutinin display species-specific immunodominance. J Clin Invest. 2018;128:4992–4996.
   PubMed Web of Science ®Google Scholar
• Erbelding EJ, Post DJ, Stemmy EJ, et al. A universal influenza vaccine: the strategic plan for the national institute of allergy and infectious diseases. J Infect Dis. 2018;218:347–354.
   PubMed Web of Science ®Google Scholar
• WHO Global Influenza Surveillance Network. Manual for the laboratory diagnosis and virological surveillance of influenza. Geneva: WHO Press; 2011.
   Google Scholar
• Lüderitz O, Staub AM, Westphal O. Immunochemistry of O and R antigens of Salmonella and related Enterobacteriaceae. Bacteriol Rev. 1966;30:192–255.
   PubMedGoogle Scholar
• Kirkpatrick E, Qiu X, Wilson PC, et al. The influenza virus hemagglutinin head evolves faster than the stalk domain. Sci Rep. 2018;8:10432.
   PubMed Web of Science ®Google Scholar
• Mathew NR, Angeletti D. Recombinant influenza vaccines: saviors to overcome immunodominance. Front Immunol. 2020;10:1–10.
   Web of Science ®Google Scholar
• Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17:1055–1065.
   PubMed Web of Science ®Google Scholar
• Ohmit SE, Petrie JG, Cross RT, et al. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J Infect Dis. 2011;204:1879–1885.
   PubMed Web of Science ®Google Scholar
• Lubeck MD, Gerhard W. Topological mapping of antigenic sites on the influenza A/PR/8/34 virus hemagglutinin using monoclonal antibodies. Virology. 1981;113:64–72.
   PubMed Web of Science ®Google Scholar
• Matsuzaki Y, Sugawara K, Nakauchi M, et al. Epitope mapping of the hemagglutinin molecule of A/(H1N1)pdm09 influenza virus by using monoclonal antibody escape mutants. J Virol. 2014;88:12364–12373.
   PubMed Web of Science ®Google Scholar
• Fulop T, Larbi A, Dupuis G, et al. Immunosenescence and inflamm-aging as two sides of the same coin: friends or foes? Front Immunol. 2018;8; doi:10.3389/fimmu.2017.01960.
   PubMed Web of Science ®Google Scholar
• Pera A, Campos C, López N, et al. Immunosenescence: implications for response to infection and vaccination in older people. Maturitas. 2015;82:50–55.
   PubMed Web of Science ®Google Scholar
• Sambhara S, McElhaney JE. Immunosenescence and influenza vaccine efficacy. Curr Top Microbiol Immunol. 2009;333:413–429.
   PubMedGoogle Scholar
• Pawelec G. Age and immunity: what is “immunosenescence”? Exp Gerontol. 2018;105:4–9.
   PubMed Web of Science ®Google Scholar
• Makinodan T. Nature of the decline in antigen-induced humoral immunity with age. Mech Ageing Dev. 1980;14:165–172.
   PubMed Web of Science ®Google Scholar
• Angeletti D, Yewdell JW. Is it possible to develop a “universal” influenza virus vaccine? outflanking antibody immunodominance on the road to universal influenza vaccination. Cold Spring Harb Perspect Biol. 2018;10:1–9.
   Web of Science ®Google Scholar
• Angeletti D, Gibbs JS, Angel M, et al. Defining B cell immunodominance to viruses. Nat Immunol. 2017;18:456–463.
   PubMed Web of Science ®Google Scholar
• Kim JH, Liepkalns J, Reber AJ, et al. Prior infection with influenza virus but not vaccination leaves a long-term immunological imprint that intensifies the protective efficacy of antigenically drifted vaccine strains. Vaccine. 2016;34:495–502.
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Ott GS, Van NG, et al. The history of MF59® adjuvant: a phoenix that arose from the ashes. Expert Rev Vaccines. 2013;12:13–30.
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Rappuoli R, De Gregorio E, et al. MF59 adjuvant: the best insurance against influenza strain diversity. Expert Rev Vaccines. 2011;10:447–462.
   PubMed Web of Science ®Google Scholar
• Ko E-J, Lee Y-T, Kim K-H, et al. Effects of MF59 adjuvant on induction of isotype-switched IgG antibodies and protection after immunization with T-dependent influenza virus vaccine in the absence of CD4 + T cells. J Virol. 2016;90:6976–6988.
   PubMed Web of Science ®Google Scholar
• Della Cioppa G, Nicolay U, Lindert K, et al. Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59® adjuvant. Hum Vaccin Immunother. 2012;8:216–227.
   PubMed Web of Science ®Google Scholar
• Even-Or O, Samira S, Ellis R, et al. Adjuvanted influenza vaccines. Expert Rev Vaccines. 2013;12:1095–1108.
   PubMed Web of Science ®Google Scholar
• Galli G, Hancock K, Hoschler K, et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci U S A. 2009;106:7962–7967.
   PubMed Web of Science ®Google Scholar
• Ko EJ, Kang SM. Immunology and efficacy of MF59-adjuvanted vaccines. Hum Vaccin Immunother. 2018;14:3041–3045.
   PubMed Web of Science ®Google Scholar
• Khurana S, Verma N, Yewdell JW, et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med. 2011;3:85ra48.
   PubMed Web of Science ®Google Scholar